secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001724521-24-000159
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction
--------------------------------------------------------------------------------

- Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.
- Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.
- Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.
- Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.
- Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/0001724521-24-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/rcus-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer